{
    "organizations": [],
    "uuid": "3f7ced689d00c7439e5106cb1ad4e725fcb74ce0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-achieve-announces-prelim-data-from/brief-achieve-announces-prelim-data-from-cytisine-phase-i-ii-clinical-study-idUSFWN1QA020",
    "ord_in_thread": 0,
    "title": "BRIEF-Achieve Announces Prelim Data From Cytisine Phase I/II Clinical Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Achieve Life Sciences Inc:\n* ACHIEVE ANNOUNCES PRELIMINARY DATA FROM CYTISINE PHASE I/II MULTI-DOSE, PHARMACOKINETIC AND PHARMACODYNAMICS (PK/PD) CLINICAL STUDY\n* ACHIEVE LIFE SCIENCES INC - CYTISINE WAS WELL-TOLERATED AND REPORTED ADVERSE EVENTS WERE MOSTLY MILD AND SHORT-LIVED IN STUDY\n* ACHIEVE LIFE SCIENCES - SUBJECTS WHO DID NOT ACHIEVE ABSTINENCE HAD “SIGNIFICANT REDUCTION” IN NUMBER OF DAILY CIGARETTES SMOKED BY END OF TREATMENT\n* ACHIEVE LIFE SCIENCES INC - NO ADVERSE EVENTS WERE SEVERE, SERIOUS, OR LED TO WITHDRAWAL FROM STUDY\n* ACHIEVE LIFE SCIENCES INC - EXPECTS TO INITIATE CYTISINE PHASE 3 DEVELOPMENT PROGRAM IN MID-2018 REQUIRED FOR FDA APPROVAL OF CYTISINE IN U.S. Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T19:08:00.000+02:00",
    "crawled": "2018-02-21T21:44:02.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "achieve",
        "life",
        "science",
        "inc",
        "achieve",
        "announces",
        "preliminary",
        "data",
        "cytisine",
        "phase",
        "pharmacokinetic",
        "pharmacodynamics",
        "clinical",
        "study",
        "achieve",
        "life",
        "science",
        "inc",
        "cytisine",
        "reported",
        "adverse",
        "event",
        "mostly",
        "mild",
        "study",
        "achieve",
        "life",
        "science",
        "subject",
        "achieve",
        "abstinence",
        "significant",
        "reduction",
        "number",
        "daily",
        "cigarette",
        "smoked",
        "end",
        "treatment",
        "achieve",
        "life",
        "science",
        "inc",
        "adverse",
        "event",
        "severe",
        "serious",
        "led",
        "withdrawal",
        "study",
        "achieve",
        "life",
        "science",
        "inc",
        "expects",
        "initiate",
        "cytisine",
        "phase",
        "development",
        "program",
        "required",
        "fda",
        "approval",
        "cytisine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}